IGF-1 LR3 1mg

Here's your full detailed IGF-1 LR3 page rewrite, ready to paste:

IGF-1 LR3 — Full Product Page (Detailed Version)

Product Title:
IGF-1 LR3 (Long Arg³ IGF-1) — Synthetic Modified Insulin-Like Growth Factor Research Peptide

Short Description:
A synthetically modified analog of native human IGF-1 incorporating an extended N-terminal amino acid sequence and third-position arginine substitution for reduced IGFBP interaction and enhanced experimental persistence. Investigated in preclinical research for IGF-1R–mediated signaling pathway dynamics, PI3K/Akt and MAPK/ERK cascade activity, cellular proliferation and differentiation pathway research, and metabolic signaling mechanism investigation in controlled laboratory settings. ≥99% Purity, HPLC-Verified. Third-Party CoA Included. For in-vitro laboratory research use only.

Full Product Description:

Overview

IGF-1 LR3 (Insulin-Like Growth Factor-1 Long Arg³) is a synthetically modified analog of native human IGF-1 developed for controlled laboratory research applications. The peptide incorporates two key structural modifications: an extended N-terminal amino acid sequence and an arginine substitution at the third residue position. These modifications are designed to significantly reduce interaction with insulin-like growth factor binding proteins (IGFBPs), thereby increasing molecular availability and persistence in controlled experimental systems.

Due to its altered binding characteristics, IGF-1 LR3 is widely utilized in controlled in-vitro and in-vivo animal research studies as an investigative tool for examining growth factor–driven signaling pathway dynamics, cellular growth regulation mechanisms, differentiation process endpoint research, and metabolic pathway coordination under defined experimental conditions. All references to activity are strictly limited to non-clinical experimental research models and do not imply therapeutic or physiological use of any kind.

Biochemical Characteristics

• Peptide Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSAMSA
• Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
• Molecular Weight: 9,117.5 g/mol
• CAS Number: 946870-92-4

IGF-1 LR3 maintains the conserved tertiary structure of native IGF-1 while exhibiting modified receptor-interaction kinetics attributable to its extended N-terminal region. In experimental research models, the peptide primarily engages the insulin-like growth factor-1 receptor (IGF-1R), with secondary interaction reported at insulin receptor isoforms under defined laboratory conditions. Attenuated binding to IGF-binding proteins alters peptide distribution and degradation behavior within controlled assay environments, supporting extended-duration signaling investigation relative to native IGF-1.

Research Applications

IGF-1 LR3 is utilized in laboratory research to explore IGF-1R–mediated signaling pathway dynamics involved in mitogenic, differentiative, and survival-associated cellular processes. Typical experimental applications include:

Cell-Based Proliferation & Differentiation Research
Cell-based assay systems measuring proliferation rate endpoints, lineage commitment dynamics, apoptosis resistance pathway activity, and signaling persistence across a range of research model systems including connective tissue, epithelial, neural, hepatic, and renal cell line platforms.

Metabolic Signaling Pathway Research
Investigations examining metabolic signaling interplay between IGF-1R and insulin receptor pathway dynamics, including:

• Glucose transport mechanism pathway research
• Lipid metabolism signaling pathway endpoint investigation
• Energy-balance regulation pathway dynamics in both cellular and controlled animal research models

Receptor Pharmacology & Binding Kinetics Research
Comparative receptor pharmacology endpoint analysis examining IGF-1R binding kinetics, IGFBP interaction dynamics, and receptor engagement persistence relative to native IGF-1 under defined experimental conditions.

Extended-Duration Signaling Studies
The enhanced stability and reduced IGFBP interaction profile of IGF-1 LR3 supports extended-duration receptor engagement studies and prolonged pathway interrogation research paradigms not achievable with native IGF-1 under standard laboratory conditions.

Pathway & Mechanistic Context

In controlled experimental systems, IGF-1 LR3 activates canonical IGF-1R–dependent signaling networks, most notably the PI3K/Akt and MAPK/ERK pathways. These signaling cascades regulate transcriptional programs governing:

• Cell-cycle progression pathway dynamics and mitogenic signaling endpoint research
• Differentiation signaling pathway activity and lineage commitment mechanism investigation
• Apoptosis suppression pathway dynamics and cellular survival signaling research

The reduced clearance profile associated with IGF-1 LR3 in experimental systems allows for extended receptor engagement, supporting prolonged pathway interrogation compared with native IGF-1 in controlled laboratory research studies.

Preclinical literature also explores cross-talk between IGF-1 signaling pathway dynamics and myostatin-associated regulatory pathway activity. These interactions are examined experimentally to investigate transcriptional control mechanisms involving MyoD-related signaling and the balance between growth-promoting and growth-limiting molecular networks in skeletal muscle research model systems.

Preclinical Research Summary

Preclinical investigations involving IGF-1 LR3 include in-vitro cell culture experiments and controlled in-vivo animal studies assessing the following experimental endpoints:

• Cellular proliferation index dynamics and mitogenic signaling pathway activity
• Differentiation potential markers and lineage commitment endpoint analysis
• Metabolic signaling behavior and glucose-uptake pathway dynamics
• Tissue-maintenance marker expression profiles under defined experimental conditions
• Differential expression of genes associated with growth regulation pathway activity

Controlled animal research models have also been utilized to study IGF-1–linked signaling pathway dynamics in the context of:

• Aging-associated molecular pathway investigation
• Glucocorticoid-responsive signaling system research
• Metabolic adaptation endpoint modeling under defined experimental conditions

All observations are interpreted exclusively within a non-clinical research framework and do not represent clinical outcomes of any kind.

Form & Analytical Testing

IGF-1 LR3 is supplied as a synthetic research-grade peptide intended for controlled laboratory handling and research workflows. Product identity and purity are verified using:

• HPLC — purity profiling and lot consistency verification
• Mass Spectrometry (MS) — molecular identity confirmation

Batch-specific documentation including certificates of analysis supporting molecular identity and purity specifications is provided where available.

Purity & Quality

• ≥99% Purity — HPLC Verified
• Independently tested by accredited third-party laboratory
• Certificate of Analysis (CoA) available for every batch

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Bodily introduction of any kind into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.

All IGF-1 LR3 research compounds supplied by P1 Peptides are produced using lyophilization — also referred to as cryodesiccation — a controlled dehydration technique widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, peptide solutions are first frozen and then subjected to reduced pressure conditions, allowing frozen water to transition directly from solid to gaseous state through sublimation — bypassing the liquid phase entirely. This removes residual moisture while fully preserving peptide structure, resulting in a dry, porous crystalline material commonly referred to as a lyophilized peptide.

The resulting white powder-like solid may be stored at room temperature for limited durations prior to reconstitution, supporting improved shelf stability and flexible handling before experimental preparation. In its lyophilized form, IGF-1 LR3 research compounds remain stable for shipping for approximately 3–4 months under standard conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, IGF-1 LR3 is typically prepared using bacteriostatic water under controlled laboratory conditions. Once reconstituted, the peptide solution should be stored under refrigerated conditions to maintain molecular integrity and compound stability. Following reconstitution, peptide solutions typically retain stability for up to 30 days when kept appropriately refrigerated.

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Receipt — Protect from heat and direct light exposure immediately upon receipt and maintain in a cool environment
• Near-Term Use (days, weeks, or a few months) — Short-term refrigeration below 4°C (39°F) is generally sufficient to maintain compound integrity
• Room Temperature Storage — Lyophilized IGF-1 LR3 is typically stable at ambient temperature for several weeks; however refrigeration is recommended when feasible to minimize degradation risk prior to reconstitution

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (several months to multiple years) — Storage in an ultra-low temperature freezer at approximately −80°C (−112°F) is strongly preferred for long-term compound preservation
• Freezing under these conditions provides optimal preservation of peptide structure and stability across extended research timelines

Post-Reconstitution Storage

• Store reconstituted solutions under refrigeration below 4°C (39°F), away from direct light and heat sources
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.